Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252573 | 0.83 | CHRNB2 (0.46) | EPHX2KDM5A | |
| SCHEMBL21424283 | 0.81 | EPHX1 (0.59) | EPHX2EPHX1 | |
| SCHEMBL23011797 | 0.81 | EPHX2 (0.51) | EPHX2KDM5ANPY5RMEN1KMT2A | |
| SCHEMBL18560182 | 0.81 | EPHX2 (0.51) | EPHX2KDM5ANPY5RMEN1KMT2A | |
| SCHEMBL23573294 | 0.81 | EPHX2 (0.51) | EPHX2NPY5RNPSR1MEN1KMT2A | |
| SCHEMBL20665186 | 0.80 | HSD11B1 (0.50) | EPHX2MEN1KMT2A | |
| SCHEMBL30884707 | 0.79 | EPHX2 (0.51) | EPHX2NPY5RMEN1KMT2AEPHX1 | |
| SCHEMBL12719747 | 0.79 | ALDH1A1 (0.50) | EPHX2KDM5A | |
| SCHEMBL12846737 | 0.79 | EPHX2 (0.49) | EPHX2KDM5AMEN1KMT2AEPHX1 | |
| SCHEMBL22917223 | 0.78 | EPHX2 (0.51) | EPHX2NPY5REPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20210024540-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024540-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | EPHX2 4750/4885KDM5A 4156/4885NPY5R 4768/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | EPHX2 4750/4885KDM5A 4156/4885NPY5R 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.